neoadjuvant combined chemotherapy with gemcitabine, cisplatin and zoledronic acid against muscle invasive bladder cancer

neoadjuvant combined chemotherapy with gemcitabine, cisplatin and zoledronic acid against muscle invasive bladder cancer - neoadjuvant combined chemotherapy with gemcitabine, cisplatin and zoledronic acid against muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003146

Enrollment

Registered

2010-02-08

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

1 course per 3 weeks GEM 800mg/m2 day1,8 , CDDP 70mg/m2 day2, Zometa 4mg day2 Total 2 courses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathological bladder cancer. 20 years old and older. Performance Status(P.S.): 0-1 The function of key organs (bone marrow, liver and kidney) is fully conserverd. Above 6 months survival is prosmising.

Exclusion criteria

Exclusion criteria: overt infection. fever(>38 degree) catastrophic complication active double cancer asymptomatic brain metastases pleural effusion pericarium varicella moror parallysis or peripheral nervedisorder drug sensitivity pregnant woman, and have possibility

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
safety survival(over all survival, progression free survival)	—

Countries

Japan

Contacts

Public ContactKoji Mita, Kanao Kobayashi

Graduate School of Biomedical Sciences, Hiroshima University Department of Urology

082-257-5242

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026